Codexis股票讨论区

follow for daily watchlist 🔥
$辉瑞(PFE.US)$ $雅培(ABT.US)$ $第一资本信贷(COF.US)$ $Codexis(CDXS.US)$ $喜玛庆国际(SGMA.US)$ $Guardforce AI(GFAI.US)$ $22nd Century(XXII.US)$ $Quoin Pharmaceuticals(QNRX.US)$ $Digital World Acquisition Corp(DWAC.US)$ $Rivian Automotive(RIVN.US)$

Gainers:
• $Vertical Aerospace(EVTL.US)$ +46.2% (FLYINGGROUP, one of Europe’s leading business jet operators, has conditionally pre-ordered up to 50 VX4 aircraft)
• $Pinterest(PINS.US)$ +15% (activist Elliott Mgmt has built a 9+% stake, according to WSJ)
• $花旗集团(C.US)$ +4.6% (Citigroup Q2 EPS $2.19 Beats $1.69 Estimate, Sales $19.60B Beat $18.12B Estimate)
• $红罗宾(RRGB.US)$ +3.2% (names new CEO)
• $NexGen Energy(NXE.US)$ +2...

Upgrades
• $Baker Hughes(BKR.US)$ : Wells Fargo Upgrades to Overweight from EqualWeight - PT $43
• $CDW Corp(CDW.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $214 (from $201)
• $Core & Main(CNM.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $34 (from $32)
• $Five Below(FIVE.US)$ : Citigroup Upgrades to Buy from Neutral - PT $205 (from $176)
• $Vector(VGR.US)$ : Barclays Uprages to Overweight from Equal Weight - PT $16 (from ...

ETFs managed by Cathie Wood’s ArkInvestment Management sold 1.19m shares in Z Holdings.
ARK's Buys
$小牛电动(NIU.US)$ $Robinhood(HOOD.US)$ $Coinbase(COIN.US)$ $DraftKings(DKNG.US)$ $UiPath(PATH.US)$
ARK's Sells
$铱星通讯(IRDM.US)$ $Codexis(CDXS.US)$ $Ionis Pharmaceuticals(IONS.US)$ $10x Genomics(TXG.US)$ $Unity Software(U.US)$ $Zillow-C(Z.US)$

Ark Investment Management sold 1.15 million Farfetch shares
Sells $Farfetch(FTCH.US)$ $Opendoor Technologies(OPEN.US)$ $Meta Platforms(FB.US)$ $Codexis(CDXS.US)$ $特斯拉(TSLA.US)$
Buys $Invitae(NVTA.US)$ $StoneCo(STNE.US)$ $小牛电动(NIU.US)$ $Roku Inc(ROKU.US)$

$Codexis(CDXS.US)$ $辉瑞(PFE.US)$
Pfizer disclosed purchase orders totaling $29 million.
Codexis said the orders are for the delivery of the company's enzyme products, which will be used in the production of Pfizer's Novel Coronavirus 19 drug candidate PF-07321332.
On June 17 and August 25, CDXS announced receipt of purchase orders for the production of unnamed active pharmaceutica intermediates in drug candidates.
In September, Pfizer announced the initiation of a Phase 2/3 clinical study to evaluate the efficacy of PF-07321332 in combination with low-dose ritonavir for the prevention of Novel Coronavirus-19.